First Page | Meta Content | |
---|---|---|
Document Date: 2014-06-24 11:09:41Open Document File Size: 390,35 KBShare Result on FacebookCityDeerfield / Copenhagen / /CompanyChelsea Therapeutics NORTHERA / Chelsea Therapeutics International Ltd. / H. Lundbeck A/S / Lundbeck U.S. / Lundbeck H. Lundbeck A/S / NASDAQ Capital Market / /CountryItaly / Mexico / France / Japan / United States / China / Denmark / /CurrencyUSD / DKK / EUR / /EventEarnings Announcement / M&A / /IndustryTermHYPERTENSION Monitor / indirect subsidiary / pharmaceutical / healthcare professionals / /MedicalConditionpure autonomic failure / mental health disorders / rare diseases / headache / brain disorders / Ischemic Heart Disease / nausea / Huntington’s disease / Parkinson's disease / fatigue / rare neurological disorders / neuroleptic malignant syndrome / muscle rigidity / Congestive Heart Failure / Alzheimer’s disease / chronic condition / hypertension / dopamine beta-hydroxylase deficiency / symptomatic neurogenic orthostatic hypotension / schizophrenia / bronchial asthma / supine hypertension / brain diseases / stroke / fainting episodes / non-diabetic autonomic neuropathy / fever / multiple system atrophy / psychiatric disorders / involuntary movements / Parkinson’s disease / Allergic Reactions / neurogenic disorder / epilepsy / dizziness / aspirin hypersensitivity / orthostatic dizziness / syndrome / lightheadedness / /MedicalTreatmentinnovative therapies / /OrganizationU.S. Food and Drug Administration / /PersonStaffan Schüberg / Torsten Madsen / Joseph G. Oliveto / / /Positionexecutive officer / president / president & chief / head / chief medical officer and vice president of U.S. Drug Development / /ProvinceOrStateIllinois / /Technologyneuroscience / Drug Development / /URLwww.lundbeck.com / www.LundbeckUS.com / /SocialTag |